Tibet Duo Rui Pharmaceutical Co

Tibet Duo Rui Pharmaceutical Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Tibet Duo Rui Pharmaceutical Co (301075.SZ) as of Nov 4, 2026 is -7.37 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -5.38 % — a change of 36.96% (lower).

EBIT/Assets

-7.37 %

YoY

36.96%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Tibet Duo Rui Pharmaceutical Co is 2025 -7.37 % . Operating Income to Assets Ratio (EBIT/Assets) of Tibet Duo Rui Pharmaceutical Co was 2024 -5.38 % . It decreases by 36.96% lower compared to the previous year.

The Tibet Duo Rui Pharmaceutical Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
22.74 CNY
Jan 1, 2019
28.35 CNY
Jan 1, 2020
28.16 CNY
Jan 1, 2021
8.82 CNY
Jan 1, 2022
1.84 CNY
Jan 1, 2023
1.11 CNY
Jan 1, 2024
-5.38 CNY
Jan 1, 2025
-7.37 CNY
The Tibet Duo Rui Pharmaceutical Co EBIT/Assets history
YEAREBIT/AssetsYoY
-7.37 %+36.96%
-5.38 %-582.75%
1.11 %-39.61%
1.84 %-79.10%
8.82 %-68.66%
28.16 %-0.67%
28.35 %+24.66%
22.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Tibet Duo Rui Pharmaceutical Co Stock analysis

What does Tibet Duo Rui Pharmaceutical Co do? Tibet Duo Rui Pharmaceutical Co., Ltd. generates revenue through the research, development, manufacture, and sale of chemical preparations and their raw materials. The company's core product, sodium acetate ringer injection, is used for supplementing body fluids, regulating electrolyte balance, and correcting acidosis. Additional products include compound electrolyte injection, compound mannitol injection, and cefotaxime sodium for injection, which are sold to healthcare providers and hospitals. The firm targets the pharmaceutical market segment focused on fluid and electrolyte management and antibiotic treatments. The company's revenue streams are derived from the sale of its proprietary chemical preparations, with sodium acetate ringer injection representing a key product line. Compound electrolyte injection and compound mannitol injection cater to specific medical needs, while cefotaxime sodium for injection serves as an antibiotic solution. These products are distributed to hospitals and healthcare facilities within China's pharmaceutical distribution network. Tibet Duo Rui Pharmaceutical's business model centers on developing and commercializing specialized injectable solutions for clinical use. The firm's product portfolio addresses critical healthcare requirements, including fluid replacement, electrolyte regulation, and infection treatment. Sales are directed toward medical institutions that require these specialized pharmaceutical products for patient care. Tibet Duo Rui Pharmaceutical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tibet Duo Rui Pharmaceutical Co stock

Operating Income to Assets Ratio (EBIT/Assets) of Tibet Duo Rui Pharmaceutical Co is -7.37 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Tibet Duo Rui Pharmaceutical Co changed from -5.38 % to -7.37 %, representing a 36.96% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Tibet Duo Rui Pharmaceutical Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Tibet Duo Rui Pharmaceutical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Tibet Duo Rui Pharmaceutical Co

All Key Metrics — Tibet Duo Rui Pharmaceutical Co